introduction estimated 2.4 million people united state chronic hepatitis virus hcv infection veteran higher rate 5.4 general u.s. population 1.8 treatment recommended person living hcv life expectancy month department veteran affair leader hepatitis treatment particularly advent direct-acting antiviral daas pillar elimination initiative novel hcv screening treatment program including mid-level provider care management telehealth furthermore covid-19 pandemic impacted hcv screening treatment emphasizing increased need telehealth intervention hcv generally hepatitis virus antibody testing decreased april hepatitis virus rna-positive result fell march continued reduction july hepatitis virus treatment prescription decreased may june july compared corresponding month highlighting importance novel method screening linkage care treatment indeed one barrier hcv evaluation treatment may timely access hcv provider study outlined difficulty specialist referral long specialist wait time barrier hcv treatment quickly identifying appropriate hcv provider limiting confusion person living hcv important component effective treatment vaglahs hepatitis e-consult direct-to-treatment dtt program established march november expedite treatment evaluation pilot program primary care provider offered option select e-consult hcv management midlevel practitioner reviewed electronic medical record determine treatment eligibility within business day used algorithm determine hcv treatment eligibility deemed eligible midlevel practitioner contacted veteran directly initiated hcv therapy deemed ineligible veteran directed evaluation infectious diseases/hepatology service standard care defined treatment evaluation usual referral pathway required initial face face visit infectious diseases/hepatology clinic program operated march 2016–november evaluate way improve hcv care delivery daa pandemic era sought characterize historical pilot program veteran referred hcv e-consult dtt program compare health care utilization clinical outcome patient initiated hcv treatment via dtt versus referral via soc practice method retrospective chart review study conducted vaglahs evaluate hcv e-consult mechanism fig adult year older hcv e-consult submitted march november included figure hcv e-consult process full size image data collected via chart review vaglahs using computerized patient record system demographic information age gender race ethnicity social history medical history collected time hcv e-consult evaluation treatment eligibility criterion highlighted supplemental table briefly patient without clinical cirrhosis fibrosis substance abuse disorder alcohol use disorder malignancy mental health disorder chronic obstructive pulmonary disease heart disease eligible inclusion endpoint included hcv treatment initiation yes/no hcv treatment completion yes/no svr12 defined week post-treatment number hcv treatment-related clinic visit outcome compared veteran initiated treatment via dtt patient ineligible dtt referred standard care descriptive statistic t-tests chi-squared test used table demographic clinical outcome full size table achievement svr12 based upon patient completed svr12 lab completed treatment reach svr12 one patient virologic failure missed lab collection adverse event reported common event evaluated based patient hcv clinical treatment note included headache nausea fatigue diarrhea weight loss insomnia suppressed appetite itchy redness burning lower extremity one person discontinued hcv treatment due adverse event ethic approval consent participate study approved local institutional review board irb vaglahs study activity carried accordance relevant guideline informed consent waived vaglahs irb due retrospective nature investigation result one hundred ninety-four hcv e-consults completed study timeframe seven patient undetectable viral load duplicate e-consults excluded e-consults patient eligible initiate hcv treatment via dtt veteran predominantly male average age year year eligible non-eligible patient respectively 0.066 table compared eligible dtt dtt eligible patient lower rate recent drug use history drug use 0.090 similarly eligible patient lower rate recent polysubstance use vs. 0.085 baseline comorbidities similar among group except malignancy lower dtt eligible patient 0.037 hcv genotype similarly distributed two group apart genotype frequent dtt eligible patient vs. eligible patient also lower fib-4 1.44 0.42 vs. 2.62 1.83 0.001 apri score 0.41 0.19 vs. 0.79 0.72 0.001 none eligible patient advanced fibrosis compared non-eligible patient 0.001 veteran received treatment initiated dtt program opposed received soc 0.034 dtt group also fewer mean face-to-face clinic visit hcv treatment 3.0 0.7 4.2 1.3 0.001 patient starting treatment dtt soc mean time hcv treatment initiation 90.4 66.9 106.4 69.4 day 0.210 treatment completion 0.822 similar importantly svr12 rate similar 0.939 rate adverse event also comparable dtt soc 0.353 table discussion retrospective chart review evaluated historical hcv e-consult dtt program aim comparing clinical outcome patient initiated hcv treatment via dtt versus soc practice veteran eligible dtt likely initiate daa therapy also trend towards shorter time hcv treatment initiation patient initiated via dtt compared ineligible patient referred specialist hcv treatment completion svr12 rate similar group dtt group fewer face-to-face clinic visit hcv treatment knowledge first evaluation program referred patient directly remote online evaluation system hcv e-consult dtt program subsequent successful hcv treatment initiation completion midlevel provider highlighting potential model integrated healthcare system exist telehealth program demonstrated effective hcv treatment particular note one study found site offered video conferencing primary care provider people living hcv part hcv va-echo program higher treatment initiation rate site offer however program others utilize e-consult dtt model reported novelty e-consult dtt program lie potential reduced time hcv diagnosis treatment furthermore dtt program implication pandemic-era loss screening linkage care treatment initiation covid-19 pandemic saw reduced hcv screening treatment across population telehealth intervention close gap offering safer convenient healthcare alternative people affected pandemic report svr12 rate program program implemented remote linkage care and/or treatment found similar success svr rate 93.3–98.5 however program differed model described important way linkage care treatment either managed exclusively managed midlevel practitioner take place integrated healthcare system exclusively evaluated people inject drug pwid cohort evaluated year ago advance telehealth outreach technology since moving forward data important due demonstration effectiveness telehealth dtt intervention time program prevalent success program linking veteran care achieving svr underline utility telehealth program midlevel provider particularly specialist often accessible additionally important note telehealth program established substance abuse alcohol abuse disorder likely given opportunity treated via electronic mean limitation include limited sample size short study timeframe second study completed single healthcare facility veteran thus result may applicable population study also evaluate patient acceptance program include quality life index received treatment via soc likely disparate population compared referred dtt regard higher proportion dtt patient initiating therapy possible referred standard care comorbidities requiring diagnostic evaluation delayed care future research could evaluate clinical outcome patient similar baseline characteristic initiated treatment via dtt versus soc compared soc hcv e-consult dtt program managed midlevel practitioner required fewer visit patient achieve similar svr12 rate result may important cost-saving post-pandemic-era safety ramification overall finding lend support e-consult program integrated healthcare system